Researchers analyzed data from 22 different trials involving over 2,000 patients with gastric cancer. The study looked at the effects of combining chemotherapy with a specific type of immune cell therapy known as CIK or DC-CIK cells.
The results showed that patients who received both the immune cell therapy and chemotherapy had a significantly better overall survival rate compared to those who received chemotherapy alone. This finding suggests that adding these specific cells to standard treatment might help manage the progression of gastric cancer.
While the data shows a positive link between this combined treatment and longer survival, it is important to note that this was a meta-analysis of existing trials. The evidence comes from a combination of different studies rather than one single large trial. Patients should discuss these specific therapy options with their oncology team to understand how they might fit into an individual treatment plan.